MedTrace Logo

BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder

NCT03193398 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2021-05-11

Study results available
· View outcomes & findings →

Summary

This study will determine the efficacy, safety, and tolerability of a once-daily (QD) dose of up to 80 mg of BTRX-246040 for 8 weeks in participants with MDD.

Conditions

Interventions

DRUG

BTRX-246040 oral capsule(s)

BTRX-246040 administered once daily to patients with MDD for 8 weeks

DRUG

Placebo oral capsule(s)

administered once daily to patients with MDD for 8 weeks

Sponsors & Collaborators

  • BlackThorn Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Jane Tiller, MD · BlackThorn Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-12
Primary Completion
2018-11-12
Completion
2018-12-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03193398 on ClinicalTrials.gov